Publikationen

Für weitere Publikationen besuchen Sie bitte Pubmed

Brummer C., Singer K., Renner K., Bruss C., Hellerbrand C., Dorn C., Reichelt-Wurm S., Gronwald W., Pukrop T., Herr W., Banas M., Kreutz M.:
The spleen-liver axis supports obesity-induced systemic and fatty liver inflammation via MDSC and NKT cell enrichment
In: Molecular and Cellular Endocrinology 601 (2025), Art.Nr.: 112518
ISSN: 0303-7207
DOI: 10.1016/j.mce.2025.112518
Schmidt S., Fischer S., El Ahmad Z., Schmid R., Metzger E., Schüle R., Hellerbrand C., Arkudas A., Kengelbach-Weigand A., Kappelmann-Fenzl M., Boßerhoff AK.:
Modeling a mesenchymal cell state by bioprinting for the molecular analysis of dormancy in melanoma
In: Materials Today Bio 32 (2025), Art.Nr.: 101674
ISSN: 2590-0064
DOI: 10.1016/j.mtbio.2025.101674

Brummer C., Singer K., Brand A., Bruss C., Renner K., Herr W., Pukrop T., Dorn C., Hellerbrand C., Matos C., Kreutz M.:
Sex-Dependent T Cell Dysregulation in Mice with Diet-Induced Obesity
In: International Journal of Molecular Sciences 25 (2024), Art.Nr.: 8234
ISSN: 1422-0067
DOI: 10.3390/ijms25158234
Dorner H., Stolzer I., Mattner J., Kaminski S., Leistl S., Edrich LM., Schwendner R., Hobauer J., Sebald ATE., Leikam S., Gonzalez Acera M., Düll M., Lang R., Seidel G., Seitz T., Hellerbrand C., Fuhrmann G., Distler U., Tenzer S., Eichhorn P., Vieth M., Schramm C., Arnold P., Becker C., Weidinger C., Siegmund B., Atreya R., Leppkes M., Naschberger E., Sampaziotis F., Dietrich P., Rauh M., Wirtz S., Kremer A., Neurath M., Günther C.:
Gut Pathobiont–Derived Outer Membrane Vesicles Drive Liver Inflammation and Fibrosis in Primary Sclerosing Cholangitis–Associated Inflammatory Bowel Disease
In: Gastroenterology (2024)
ISSN: 0016-5085
DOI: 10.1053/j.gastro.2024.06.032

Kersten V., Seitz T., Sommer J., Thasler WE., Boßerhoff AK., Hellerbrand C.:
Bone Morphogenetic Protein 13 Has Protumorigenic Effects on Hepatocellular Carcinoma Cells In Vitro.
In: International Journal of Molecular Sciences 24 (2023)
ISSN: 1422-0067
DOI: 10.3390/ijms241311059
Mahli A., Thasler WE., Biendl M., Hellerbrand C.:
Hop-derived Humulinones Reveal Protective Effects in in vitro Models of Hepatic Steatosis, Inflammation and Fibrosis.
In: Planta Medica 89 (2023), S. 1138-1146
ISSN: 0032-0943
DOI: 10.1055/a-2103-3230
Ortiz C., Klein S., Reul WH., Magdaleno F., Groeschl S., Dietrich P., Schierwagen R., Uschner FE., Torres S., Hieber C., Meier C., Kraus N., Tyc O., Brol M., Zeuzem S., Welsch C., Poglitsch M., Hellerbrand C., Alfonso-Prieto M., Mira F., Keller UAD., Tetzner A., Moore A., Walther T., Trebicka J.:
Neprilysin-dependent neuropeptide Y cleavage in the liver promotes fibrosis by blocking NPY-receptor 1
In: Cell Reports 42 (2023)
ISSN: 2211-1247
DOI: 10.1016/j.celrep.2023.112059
Seitz T., Setz C., Rauch P., Schubert U., Hellerbrand C.:
Lipid Accumulation in Host Cells Promotes SARS-CoV-2 Replication
In: Viruses 15 (2023)
ISSN: 1999-4915
DOI: 10.3390/v15041026
Sommer J., Ehnis H., Seitz T., Schneider J., Wild A., Moceri S., Buechler C., Bozec A., Weber G., Merkel S., Beckervordersandforth R., Steinkasserer A., Schüle R., Trebicka J., Hartmann A., Boßerhoff AK., von Hörsten S., Dietrich P., Hellerbrand C.:
Four-and-a-Half LIM-Domain Protein 2 (FHL2) Induces Neuropeptide Y (NPY) in Macrophages in Visceral Adipose Tissue and Promotes Diet-Induced Obesity
In: International Journal of Molecular Sciences 24 (2023), Art.Nr.: 14943
ISSN: 1422-0067
DOI: 10.3390/ijms241914943
Sommer J., Thasler WE., Boßerhoff AK., Hellerbrand C.:
Expression of Bone Morphogenetic Protein 14 in Liver Disease and Cancer
In: Livers 3 (2023), S. 282-292
ISSN: 2673-4389
DOI: 10.3390/livers3020019

Joechle K., Jumaa H., Thriene K., Hellerbrand C., Kulemann B., Fichtner-Feigl S., Lang SA., Guenzle J.:
Dual Inhibition of mTORC1/2 Reduces Migration of Cholangiocarcinoma Cells by Regulation of Matrixmetalloproteinases
In: Frontiers in Cell and Developmental Biology 9 (2022), Art.Nr.: 785979
ISSN: 2296-634X
DOI: 10.3389/fcell.2021.785979
Jung F., Staltner R., Baumann A., Burger K., Halilbasic E., Hellerbrand C., Bergheim I.:
A Xanthohumol-Rich Hop Extract Diminishes Endotoxin-Induced Activation of TLR4 Signaling in Human Peripheral Blood Mononuclear Cells: A Study in Healthy Women
In: International Journal of Molecular Sciences 23 (2022), Art.Nr.: 12702
ISSN: 1422-0067
DOI: 10.3390/ijms232012702
Jung F., Staltner R., Tahir A., Baumann A., Burger K., Halilbasic E., Hellerbrand C., Bergheim I.:
Effect of the hop compound xanthohumol on lipoteichic acids-induced inflammatory processes in healthy humans
2nd World Congress on Alcohol and Alcoholism Joint meeting of ISBRA and ESBRA (Cracow, 17. September 2022 - 20. September 2022)
In: Alcohol Clin Exp Res (Hrsg.): Special Issue of Alcoholism: Clinical and Experimental Research, HOBOKEN: 2022
Jung F., Staltner R., Tahir A., Baumann A., Burger K., Halilbasic E., Hellerbrand C., Bergheim I.:
Oral intake of xanthohumol attenuates lipoteichoic acid-induced inflammatory response in human PBMCs
In: European Journal of Nutrition (2022)
ISSN: 1436-6207
DOI: 10.1007/s00394-022-02964-2
Kurz B., Arndt S., Unger P., Ivanova I., Berneburg M., Hellerbrand C., Karrer S.:
Association of polymorphous light eruption with NOD-2 and TLR-5 gene polymorphisms
In: Journal of the European Academy of Dermatology and Venereology (2022)
ISSN: 0926-9959
DOI: 10.1111/jdv.18364
Mahli A., Koch A., Seitz T., Bergheim I., Hellerbrand C.:
Xanthohumol ameliorates acute alcohol-induced liver injury
In: ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, HOBOKEN: 2022
Peschl V., Seitz T., Sommer J., Thasler W., Boßerhoff AK., Hellerbrand C.:
Bone morphogenetic protein 13 in hepatic stellate cells and hepatic fibrosis
In: Journal of Cellular Biochemistry (2022)
ISSN: 0730-2312
DOI: 10.1002/jcb.30248
Schmidt AW., Kühnapfel A., Kirsten H., Grallert H., Hellerbrand C., Kiefer F., Mann K., Mueller S., Nöthen MM., Peters A., Ridinger M., Frank J., Rietschel M., Soranzo N., Soyka M., Wodarz N., Malerba G., Gambaro G., Gieger C., Scholz M., Krug S., Michl P., Ewers M., Witt H., Laumen H., Rosendahl J.:
Colocalization analysis of pancreas eQTLs with risk loci from alcoholic and novel non-alcoholic chronic pancreatitis GWAS suggests potential disease causing mechanisms
In: Pancreatology (2022)
ISSN: 1424-3903
DOI: 10.1016/j.pan.2022.03.007
Seitz T., John N., Sommer J., Dietrich P., Thasler WE., Hartmann A., Evert K., Lang SA., Boßerhoff AK., Hellerbrand C.:
Role of Fibroblast Growth Factors in the Crosstalk of Hepatic Stellate Cells and Uveal Melanoma Cells in the Liver Metastatic Niche
In: International Journal of Molecular Sciences 23 (2022), Art.Nr.: 11524
ISSN: 1422-0067
DOI: 10.3390/ijms231911524

Fritz V., Malek L., Gaza A., Wormser L., Appel M., Kremer A., Thasler WE., Neurath M., Hellerbrand C., Boßerhoff AK., Dietrich P., Siebler J.:
Combined de‐repression of chemoresistance associated mitogen‐activated protein kinase 14 and activating transcription factor 2 by loss of microrna‐622 in hepatocellular carcinoma
In: Cancers 13 (2021), S. 1-14
ISSN: 2072-6694
DOI: 10.3390/cancers13051183
Gaza A., Fritz V., Malek L., Wormser L., Treiber N., Danner J., Kremer AE., Thasler WE., Siebler J., Meister G., Neurath MF., Hellerbrand C., Boßerhoff AK., Dietrich P.:
Identification of novel targets of miR-622 in hepatocellular carcinoma reveals common regulation of cooperating genes and outlines the oncogenic role of zinc finger CCHC-type containing 11
In: Neoplasia 23 (2021), S. 502-514
ISSN: 1522-8002
DOI: 10.1016/j.neo.2021.04.001
Guenzle J., Akasaka H., Joechle K., Reichardt W., Venkatasamy A., Hoeppner J., Hellerbrand C., Fichtner-Feigl S., Lang SA.:
Pharmacological inhibition of mtorc2 reduces migration and metastasis in melanoma
In: International Journal of Molecular Sciences 22 (2021), S. 1-16
ISSN: 1422-0067
DOI: 10.3390/ijms22010030
Joechle K., Cramer T., Neumann UP., Lang SA., Guenzle J., Hellerbrand C., Strnad P.:
Role of mammalian target of rapamycin complex 2 in primary and secondary liver cancer
In: World Journal of Gastrointestinal Oncology 13 (2021), S. 1632-1647
ISSN: 1948-5204
DOI: 10.4251/wjgo.v13.i11.1632
Mahli A., Sommer J., Koch A., Hellerbrand C.:
STEATOSIS: A LUBRICANT FOR THE DEVELOPMENT AND PROGRESSION OF ALCOHOLIC LIVER DISEASE
In: ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, HOBOKEN: 2021
Seitz T., Hackl C., Freese K., Dietrich P., Mahli A., Thasler RM., Thasler WE., Lang SA., Boßerhoff AK., Hellerbrand C.:
Xanthohumol, a prenylated chalcone derived from hops, inhibits growth and metastasis of melanoma cells
In: Cancers 13 (2021), S. 1-12
ISSN: 2072-6694
DOI: 10.3390/cancers13030511
Seitz T., Hellerbrand C.:
Role of fibroblast growth factor signalling in hepatic fibrosis
In: Liver International (2021)
ISSN: 1478-3223
DOI: 10.1111/liv.14863

Dietrich P., Wormser L., Fritz V., Seitz T., de Maria M., Schambony A., Kremer A., Günther C., Itzel T., Thasler WE., Teufel A., Trebicka J., Hartmann A., Neurath M., von Hörsten S., Boßerhoff AK., Hellerbrand C.:
Molecular cross-talk between Y5-receptor and neuropeptide Y drives liver cancer
In: Journal of Clinical Investigation 130 (2020), S. 2509-2526
ISSN: 0021-9738
DOI: 10.1172/JCI131919
Gaitantzi H., Karch J., Germann L., Cai C., Rausch V., Birgin E., Rahbari N., Seitz T., Hellerbrand C., Koenig C., Augustin HG., Mogler C., De La Torre C., Gretz N., Itzel T., Teufel A., Ebert MPA., Breitkopf-Heinlein K.:
BMP-9 Modulates the Hepatic Responses to LPS
In: Cells 9 (2020)
ISSN: 2073-4409
DOI: 10.3390/cells9030617
Koch A., Ebert EV., Seitz T., Dietrich P., Berneburg M., Boßerhoff AK., Hellerbrand C.:
Characterization of glycolysis-related gene expression in malignant melanoma
In: Pathology Research and Practice 216 (2020), Art.Nr.: 152752
ISSN: 0344-0338
DOI: 10.1016/j.prp.2019.152752
Linck-Paulus L., Hellerbrand C., Boßerhoff AK., Dietrich P.:
Dissimilar Appearances Are Deceptive-Common microRNAs and Therapeutic Strategies in Liver Cancer and Melanoma
In: Cells 9 (2020)
ISSN: 2073-4409
DOI: 10.3390/cells9010114
Schierwagen R., Dietrich P., Klein S., Uschner FE., Ortiz C., Tyc O., Torres S., Hellerbrand C., Sauerbruch T., Trebicka J.:
β-Arrestin2 is increased in liver fibrosis in humans and rodents
In: Proceedings of the National Academy of Sciences of the United States of America 117 (2020), S. 27082-27084
ISSN: 0027-8424
DOI: 10.1073/pnas.2014337117
Seitz T., Freese K., Dietrich P., Thasler WE., Boßerhoff AK., Hellerbrand C.:
Fibroblast Growth Factor 9 is expressed by activated hepatic stellate cells and promotes progression of hepatocellular carcinoma
In: Scientific Reports 10 (2020), Art.Nr.: 4546
ISSN: 2045-2322
DOI: 10.1038/s41598-020-61510-4
Sommer J., Dorn C., Gaebele E., Bataille F., Freese K., Seitz T., Thasler WE., Buettner R., Weiskirchen R., Boßerhoff AK., Hellerbrand C.:
Four-And-A-Half LIM-Domain Protein 2 (FHL2) Deficiency Aggravates Cholestatic Liver Injury
In: Cells 9 (2020)
ISSN: 2073-4409
DOI: 10.3390/cells9010248
Torres S., Abdullah Z., Brol MJ., Hellerbrand C., Fernandez M., Fiorotto R., Klein S., Königshofer P., Liedtke C., Lotersztajn S., Nevzorova YA., Schierwagen R., Reiberger T., Uschner FE., Tacke F., Weiskirchen R., Trebicka J.:
Recent advances in practical methods for liver cell biology: A short overview
In: International Journal of Molecular Sciences 21 (2020), Art.Nr.: 2027
ISSN: 1422-0067
DOI: 10.3390/ijms21062027

Arndt S., Karrer S., Hellerbrand C., Boßerhoff AK.:
Bone Morphogenetic Protein-6 Inhibits Fibrogenesis in Scleroderma Offering Treatment Options for Fibrotic Skin Disease
In: Journal of Investigative Dermatology (2019)
ISSN: 0022-202X
DOI: 10.1016/j.jid.2019.02.020
Dietrich P., Gaza A., Wormser L., Fritz V., Hellerbrand C., Boßerhoff AK.:
Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Is a Novel Prognostic Marker and Contributes to Sorafenib Resistance in Hepatocellular Carcinoma
In: Neoplasia 21 (2019), S. 257-268
ISSN: 1522-8002
DOI: 10.1016/j.neo.2018.11.011
Dietrich P., Hellerbrand C., Boßerhoff AK.:
The delta subunit of rod-specific photoreceptor cgmp phosphodiesterase (Pde6d) contributes to hepatocellular carcinoma progression
In: Cancers 11 (2019), Art.Nr.: 398
ISSN: 2072-6694
DOI: 10.3390/cancers11030398
Feuerer L., Lamm S., Henz I., Kappelmann-Fenzl M., Haferkamp S., Meierjohann S., Hellerbrand C., Kuphal S., Boßerhoff AK.:
Role of melanoma inhibitory activity in melanocyte senescence
In: Pigment Cell & Melanoma Research (2019)
ISSN: 1755-1471
DOI: 10.1111/pcmr.12801
Freese K., Dietrich P., Boßerhoff AK., Hellerbrand C.:
Variation of different histone deacetylases and the functional effects of HDAC inhibitors in hepatocellular carcinoma
International Liver Congress (Vienna, 10. April 2019 - 14. April 2019)
In: JOURNAL OF HEPATOLOGY, AMSTERDAM: 2019
DOI: 10.1016/s0618-8278(19)30712-1
Freese K., Seitz T., Dietrich P., Lee SM., Thasler WE., Boßerhoff AK., Hellerbrand C.:
Histone deacetylase expressions in hepatocellular carcinoma and functional effects of histone deacetylase inhibitors on liver cancer cells in vitro
In: Cancers 11 (2019), Art.Nr.: 1587
ISSN: 2072-6694
DOI: 10.3390/cancers11101587
Hellerbrand C.:
Inhibition of monoacylglycerol lipase for the treatment of liver disease: tempting but still playing with fire
In: Gut 68 (2019), S. 382-+
ISSN: 0017-5749
DOI: 10.1136/gutjnl-2018-317520
Kappelmann-Fenzl M., Kuphal S., Krupar R., Schadendorf D., Umansky V., Vardimon L., Hellerbrand C., Boßerhoff AK.:
Complex formation with monomeric α-tubulin and importin 13 fosters c-jun protein stability and is required for c-jun’s nuclear translocation and activity
In: Cancers 11 (2019), Art.Nr.: 1806
ISSN: 2072-6694
DOI: 10.3390/cancers11111806
Mahli A., Seitz T., Beckroege T., Freese K., Thasler WE., Benkert M., Dietrich P., Weiskirchen R., Boßerhoff AK., Hellerbrand C.:
Bone Morphogenetic Protein-8B Expression is Induced in Steatotic Hepatocytes and Promotes Hepatic Steatosis and Inflammation In Vitro
In: Cells 8 (2019)
ISSN: 2073-4409
DOI: 10.3390/cells8050457
Mahli A., Seitz T., Freese K., Frank J., Weiskirchen R., Abdel-Tawab M., Behnam D., Hellerbrand C.:
Therapeutic Application of Micellar Solubilized Xanthohumol in a Western-Type Diet-Induced Mouse Model of Obesity, Diabetes and Non-Alcoholic Fatty Liver Disease
In: Cells 8 (2019)
ISSN: 2073-4409
DOI: 10.3390/cells8040359
Mahli A., Thasler WE., Hellerbrand C.:
Establishment of a p-nitrophenol oxidation-based assay for the analysis of CYP2E1 activity in intact hepatocytes in vitro
In: Toxicology Mechanisms and Methods 29 (2019), S. 219-223
ISSN: 1537-6516
DOI: 10.1080/15376516.2018.1539800
Starkel P., Schnabl B., Leclercq S., Komuta M., Bataller R., Argemi J., Palma E., Chokshi S., Hellerbrand C., Maccioni L., Lanthier N., Leclercq I.:
Deficient IL-6/Stat3 Signaling, High TLR7, and Type I Interferons in Early Human Alcoholic Liver Disease: A Triad for Liver Damage and Fibrosis
In: Hepatology Communications 3 (2019), S. 867-882
ISSN: 2471-254X
DOI: 10.1002/hep4.1364
Stieglitz D., Lamm S., Braig S., Feuerer L., Kuphal S., Dietrich P., Arndt S., Echtenacher B., Hellerbrand C., Karrer S., Boßerhoff AK.:
BMP6-induced modulation of the tumor micro-milieu
In: Oncogene 38 (2019), S. 609-621
ISSN: 0950-9232
DOI: 10.1038/s41388-018-0475-x
Strnad P., Buch S., Hamesch K., Fischer J., Rosendahl J., Schmelz R., Brueckner S., Brosch M., Heimes CV., Woditsch V., Scholten D., Nischalke HD., Janciauskiene S., Mandorfer M., Trauner M., Way MJ., McQuillin A., Reichert MC., Krawczyk M., Casper M., Lammert F., Braun F., Von Schönfels W., Hinz S., Burmeister G., Hellerbrand C., Teufel A., Feldman A., Schattenberg JM., Bantel H., Pathil A., Demir M., Kluwe J., Boettler T., Ridinger M., Wodarz N., Soyka M., Rietschel M., Kiefer F., Weber T., Marhenke S., Vogel A., Hinrichsen H., Canbay A., Schlattjan M., Sosnowsky K., Sarrazin C., Von Felden J., Geier A., Deltenre P., Sipos B., Schafmayer C., Nothnagel M., Aigner E., Datz C., Stickel F., Morgan MY., Hampe J., Berg T., Trautwein C.:
Heterozygous carriage of the alpha1-antitrypsin Pi∗Z variant increases the risk to develop liver cirrhosis
In: Gut 68 (2019), S. 1099-1107
ISSN: 0017-5749
DOI: 10.1136/gutjnl-2018-316228

Buschauer S., Koch A., Wiggermann P., Mueller M., Hellerbrand C.:
Hepatocellular carcinoma cells surviving doxorubicin treatment exhibit increased migratory potential and resistance to doxorubicin re-treatment in vitro
In: Oncology Letters 15 (2018), S. 4635-4640
ISSN: 1792-1074
DOI: 10.3892/ol.2018.7887
Dietrich P., Freese K., Mahli A., Thasler WE., Hellerbrand C., Boßerhoff AK.:
Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic "dual-hit" option
In: Oncotarget 9 (2018), S. 3605-3618
ISSN: 1949-2553
DOI: 10.18632/oncotarget.23188
Dietrich P., Kuphal S., Spruss T., Hellerbrand C., Boßerhoff AK.:
MicroRNA-622 is a novel mediator of tumorigenicity in melanoma by targeting Kirsten rat sarcoma
In: Pigment Cell & Melanoma Research (2018)
ISSN: 1755-1471
DOI: 10.1111/pcmr.12698
Hammad S., Othman A., Meyer C., Telfah A., Lambert J., Dewidar B., Werle J., Nwosu ZC., Mahli A., Dormann C., Gao Y., Gould K., Han M., Yuan X., Gogiashvili M., Hergenroeder R., Hellerbrand C., Thomas M., Ebert MP., Amasheh S., Hengstler JG., Dooley S.:
Confounding influence of tamoxifen in mouse models of Cre recombinase-induced gene activity or modulation
In: Archives of Toxicology 92 (2018), S. 2549-2561
ISSN: 0340-5761
DOI: 10.1007/s00204-018-2254-4
Hege M., Jung F., Sellmann C., Jin C., Ziegenhardt D., Hellerbrand C., Bergheim I.:
An iso-α-acid-rich extract from hops (Humulus lupulus) attenuates acute alcohol-induced liver steatosis in mice
In: Nutrition 45 (2018), S. 68-75
ISSN: 0899-9007
DOI: 10.1016/j.nut.2017.07.010
Kim F., Hellerbrand C.:
Increased expression of pregnancy-associated plasma protein-A in activated hepatic stellate cells is a potential therapeutic target and serum marker of hepatic fibrosis
International Liver Congress (ILC) (Paris, 11. April 2018 - 15. April 2018)
In: JOURNAL OF HEPATOLOGY, AMSTERDAM: 2018
DOI: 10.1016/s0168-8278(18)31019-5
Mahli A., Koch A., Fresse K., Schiergens T., Thasler WE., Schoenberger C., Bergheim I., Boßerhoff AK., Hellerbrand C.:
Iso-alpha acids from hops (Humulus lupulus) inhibit hepatic steatosis, inflammation, and fibrosis
In: Laboratory Investigation 98 (2018), S. 1614-1626
ISSN: 0023-6837
DOI: 10.1038/s41374-018-0112-x
Mahli A., Koch A., Thasler W., Hellerbrand C.:
Hepatic steatosis potentiates irinotecan-induced hepatocellular injury via dysregulation of irinotecan-metabolizing enzymes
International Liver Congress (ILC) (Paris, 11. April 2018 - 15. April 2018)
In: JOURNAL OF HEPATOLOGY, AMSTERDAM: 2018
DOI: 10.1016/s0168-8278(18)30941-3
Reichel M., Rhein C., Hofmann LM., Monti J., Japtok L., Langgartner D., Fuechsl AM., Kleuser B., Gulbins E., Hellerbrand C., Reber SO., Kornhuber J.:
Chronic Psychosocial Stress in Mice Is Associated With Increased Acid Sphingomyelinase Activity in Liver and Serum and With Hepatic C16:0-Ceramide Accumulation
In: Frontiers in Psychiatry 9 (2018)
ISSN: 1664-0640
DOI: 10.3389/fpsyt.2018.00496
Schmidt KM., Dietrich P., Hackl C., Guenzle J., Bronsert P., Wagner C., Fichtner-Feigl S., Schlitt HJ., Geissler EK., Hellerbrand C., Lang SA.:
Inhibition of mTORC2/RICTOR Impairs Melanoma Hepatic Metastasis
In: Neoplasia 20 (2018), S. 1198-1208
ISSN: 1522-8002
DOI: 10.1016/j.neo.2018.10.001
Sommer J., Hellerbrand C.:
Four-and-a-half LIM-domain protein affects diet induced (hepatic) steatosis and lipid droplet formation
International Liver Congress (ILC) (Paris, 11. April 2018 - 15. April 2018)
In: JOURNAL OF HEPATOLOGY, AMSTERDAM: 2018
DOI: 10.1016/s0168-8278(18)30918-8

Breitkopf-Heinlein K., Meyer C., Koenig C., Gaitantzi H., Addante A., Thomas M., Wiercinska E., Cai C., Li Q., Wan F., Hellerbrand C., Valous NA., Hahnel MJ., Ehlting C., Bode JG., Mueller-Bohl S., Klingmueller U., Altenoeder J., Ilkavets I., Goumans MJ., Hawinkels LJAC., Lee SJ., Wieland M., Mogler C., Ebert MP., Herrera B., Augustin HG., Sanchez A., Dooley S., Ten Dijke P.:
BMP-9 interferes with liver regeneration and promotes liver fibrosis
In: Gut 66 (2017), S. 939-954
ISSN: 0017-5749
DOI: 10.1136/gutjnl-2016-313314
Dietrich P., Koch A., Fritz V., Hartmann A., Boßerhoff AK., Hellerbrand C.:
Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance
In: Gut (2017)
ISSN: 0017-5749
DOI: 10.1136/gutjnl-2017-315402
Dietrich P., Kuphal S., Spruss T., Hellerbrand C., Boßerhoff AK.:
Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition
In: Oncogene (2017)
ISSN: 0950-9232
DOI: 10.1038/onc.2017.391
Krenkel O., Puengel T., Govaere O., Abdallah AT., Mossanen JC., Kohlhepp M., Liepelt A., Lefebvre E., Luedde T., Hellerbrand C., Weiskirchen R., Longerich T., Costa IG., Anstee QM., Trautwein C., Tacke F.:
Therapeutic Inhibition of Inflammatory Monocyte Recruitment Reduces Steatohepatitis and Liver Fibrosis
In: Hepatology (2017)
ISSN: 0270-9139
DOI: 10.1002/hep.29544
Krupar R., Hautmann MG., Pathak RR., Varier I., Mclaren C., Gaag D., Hellerbrand C., Evert M., Laban S., Idel C., Sandulache V., Perner S., Boßerhoff AK., Sikora AG.:
Immunometabolic Determinants of Chemoradiotherapy Response and Survival in Head and Neck Squamous Cell Carcinoma
In: American Journal of Pathology (2017)
ISSN: 0002-9440
DOI: 10.1016/j.ajpath.2017.09.013
Kuphal S., Schneider N., Massoumi R., Hellerbrand C., Boßerhoff AK.:
UVB radiation represses CYLD expression in melanocytes
In: Oncology Letters 14 (2017), S. 7262-7268
ISSN: 1792-1074
DOI: 10.3892/ol.2017.7120
Sommer J., Mahli A., Freese K., Schiergens TS., Kuecuekoktay FS., Teufel A., Thasler WE., Mueller M., Boßerhoff AK., Hellerbrand C.:
Analysis of molecular mechanisms of 5-fluorouracil-induced steatosis and inflammation in vitro and in mice
In: Oncotarget 8 (2017), S. 13059-13072
ISSN: 1949-2553
DOI: 10.18632/oncotarget.14371
Yang AM., Inamine T., Hochrath K., Chen P., Wang L., Llorente C., Bluemel S., Hartmann P., Xu J., Koyama Y., Kisseleva T., Torralba MG., Moncera K., Beeri K., Chen CS., Freese K., Hellerbrand C., Lee SML., Hoffman HM., Mehal WZ., Garcia-Tsao G., Mutlu EA., Keshavarzian A., Brown GD., Ho SB., Bataller R., Starkel P., Fouts DE., Schnabl B.:
Intestinal fungi contribute to development of alcoholic liver disease
In: Journal of Clinical Investigation 127 (2017), S. 2829-2841
ISSN: 0021-9738
DOI: 10.1172/JCI90562

Schicho A, Hellerbrand C, Krüger K, Beyer LP, Wohlgemuth W, Niessen C, Hohenstein E, Stroszczynski C, Pereira PL, Wiggermann P.
Impact of Different Embolic Agents for Transarterial Chemoembolization (TACE) Procedures on Systemic Vascular Endothelial Growth Factor (VEGF) Levels.
J Clin Transl Hepatol. 2016 Dec 284(4):288-292. doi: 10.14218/JCTH.2016.00058.

Sommer J, Mahli A, Freese K, Schiergens TS, Kuecuekoktay FS, Teufel A, Thasler WE, Müller M, Bosserhoff AK, Hellerbrand C.
Analysis of molecular mechanisms of 5-fluorouracil-induced steatosis and inflammation in vitro and in mice.
Oncotarget. 2016 Dec 30. doi: 10.18632/oncotarget.14371. [Epub ahead of print]

Mahli A, Hellerbrand C.
Alcohol and Obesity: A Dangerous Association for Fatty Liver Disease.
Dig Dis. 201634 Suppl 1:32-9. doi: 10.1159/000447279. Review.

Teufel A, Itzel T, Erhart W, Brosch M, Wang XY, Kim YO, von Schönfels W, Herrmann A, Brückner S, Stickel F, Dufour JF, Chavakis T, Hellerbrand C, Spang R, Maass T, Becker T, Schreiber S, Schafmayer C, Schuppan D, Hampe J.
Comparison of Gene Expression Patterns Between Mouse Models of Nonalcoholic Fatty Liver Disease and Liver Tissues From Patients.
Gastroenterology. 2016 Sep151(3):513-525.e0. doi: 10.1053/j.gastro.2016.05.051.

Hellerbrand C, Massoumi R.
Cylindromatosis–A Protective Molecule against Liver Diseases.
Med Res Rev. 2016 Mar36(2):342-59. doi: 10.1002/med.21381. Review.

Roeb E, Steffen HM, Bantel H, Baumann U, Canbay A, Demir M, Drebber U, Geier A, Hampe J, Hellerbrand C, Pathil-Warth A, Schattenberg JM, Schramm C, Seitz HK, Stefan N, Tacke F, Tannapfel A, Lynen Jansen P, Bojunga J.
[S2k Guideline non-alcoholic fatty liver disease].
Z Gastroenterol. 2015 Jul;53(7):668-723.

Scheller T, Hellerbrand C, Moser C, Schmidt K, Kroemer A, Brunner SM, Schlitt HJ, Geissler EK, Lang SA.
mTOR inhibition improves fibroblast growth factor receptor targeting in hepatocellular carcinoma.
Br J Cancer. 2015 Mar 3;112(5):841-50.

Schmidt K, Moser C, Hellerbrand C, Zieker D, Wagner C, Redekopf J, Schlitt HJ, Geissler EK, Lang SA.
Targeting Fibroblast Growth Factor Receptor (FGFR) with BGJ398 in a Gastric Cancer Model.
Anticancer Res. 2015 Dec35(12):6655-65.

Siegert I, Schödel J, Nairz M, Schatz V, Dettmer K, Dick C, Kalucka J, Franke K, Ehrenschwender M, Schley G, Beneke A, Sutter J, Moll M, Hellerbrand C, Wielockx B, Katschinski DM, Lang R, Galy B, Hentze MW, Koivunen P, Oefner PJ, Bogdan C, et al.
Ferritin-Mediated Iron Sequestration Stabilizes Hypoxia-Inducible Factor-1α upon LPS Activation in the Presence of Ample Oxygen.
Cell Rep. 2015 Dec 1513(10):2048-55. doi: 10.1016/j.celrep.2015.11.005.

Mahli A, Thasler WE, Patsenker E, Müller S, Stickel F, Müller M, Seitz HK, Cederbaum AI, Hellerbrand C.
Identification of cytochrome CYP2E1 as critical mediator of synergistic effects of alcohol and cellular lipid accumulation in hepatocytes in vitro.
Oncotarget. 2015 Dec 86(39):41464-78. doi: 10.18632/oncotarget.6203.

Buch S, Stickel F, Trépo E, Way M, Herrmann A, Nischalke HD, Brosch M, Rosendahl J, Berg T, Ridinger M, Rietschel M, McQuillin A, Frank J, Kiefer F, Schreiber S, Lieb W, Soyka M, Semmo N, Aigner E, Datz C, Schmelz R, Brückner S, et al.
A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis.
Nat Genet. 2015 Dec47(12):1443-8. doi: 10.1038/ng.3417.

Koch A, Lang SA, Wild PJ, Gantner S, Mahli A, Spanier G, Berneburg M, Müller M, Bosserhoff AK, Hellerbrand C.
Glucose transporter isoform 1 expression enhances metastasis of malignant melanoma cells.
Oncotarget. 2015 Oct 206(32):32748-60. doi: 10.18632/oncotarget.4977.

Ruedel A, Dietrich P, Schubert T, Hofmeister S, Hellerbrand C, Bosserhoff AK.
Expression and function of microRNA-188-5p in activated rheumatoid arthritis synovial fibroblasts.
Int J Clin Exp Pathol. 2015 Jun 18(6):6607-16. Retraction in: Int J Clin Exp Pathol. 20158(11):15497.

Seitz HK, Mueller S, Hellerbrand C, Liangpunsakul S.
Effect of chronic alcohol consumption on the development and progression of non-alcoholic fatty liver disease (NAFLD).
Hepatobiliary Surg Nutr. 2015 Jun4(3):147-51. doi: 10.3978/j.issn.2304-3881.2014.12.01. Review.

Roy S, Benz F, Vargas Cardenas D, Vucur M, Gautheron J, Schneider A, Hellerbrand C, Pottier N, Alder J, Tacke F, Trautwein C, Roderburg C, Luedde T.
miR-30c and miR-193 are a part of the TGF-β-dependent regulatory network controlling extracellular matrix genes in liver fibrosis.
J Dig Dis. 2015 Sep16(9):513-24. doi: 10.1111/1751-2980.12266.

Engelmann JC, Amann T, Ott-Rötzer B, Nützel M, Reinders Y, Reinders J, Thasler WE, Kristl T, Teufel A, Huber CG, Oefner PJ, Spang R, Hellerbrand C.
Causal Modeling of Cancer-Stromal Communication Identifies PAPPA as a Novel Stroma-Secreted Factor Activating NFκB Signaling in Hepatocellular Carcinoma.
PLoS Comput Biol. 2015 May 2811(5):e1004293. doi: 10.1371/journal.pcbi.1004293.

Weiskirchen R, Mahli A, Weiskirchen S, Hellerbrand C.
The hop constituent xanthohumol exhibits hepatoprotective effects and inhibits the activation of hepatic stellate cells at different levels.
Front Physiol. 2015 May 66:140. doi: 10.3389/fphys.2015.00140. Review.

Herrnberger L, Hennig R, Kremer W, Hellerbrand C, Goepferich A, Kalbitzer HR, Tamm ER.
Formation of fenestrae in murine liver sinusoids depends on plasmalemma vesicle-associated protein and is required for lipoprotein passage.
PLoS One. 2014 Dec 269(12):e115005. doi: 10.1371/journal.pone.0115005.

Padrissa-Altés S, Bachofner M, Bogorad RL, Pohlmeier L, Rossolini T, Böhm F, Liebisch G, Hellerbrand C, Koteliansky V, Speicher T, Werner S.
Control of hepatocyte proliferation and survival by Fgf receptors is essential for liver regeneration in mice.
Gut. 2015 Sep64(9):1444-53.

Bauer R, Valletta D, Bauer K, Thasler WE, Hartmann A, Müller M, Reichert TE, Hellerbrand C.
Downregulation of P-cadherin expression in hepatocellular carcinoma induces tumorigenicity.
Int J Clin Exp Pathol. 2014 Aug 157(9):6125-32.

Dietrich P, Hellerbrand C.
Non-alcoholic fatty liver disease, obesity and the metabolic syndrome.
Best Pract Res Clin Gastroenterol. 2014 Aug28(4):637-53. doi: 10.1016/j.bpg.2014.07.008. Review.

Krupar R, Robold K, Gaag D, Spanier G, Kreutz M, Renner K, Hellerbrand C, Hofstaedter F, Bosserhoff AK.
Immunologic and metabolic characteristics of HPV-negative and HPV-positive head and neck squamous cell carcinomas are strikingly different.
Virchows Arch. 2014 Sep465(3):299-312. doi: 10.1007/s00428-014-1630-6.

Arndt S, Wacker E, Dorn C, Koch A, Saugspier M, Thasler WE, Hartmann A, Bosserhoff AK, Hellerbrand C.
Enhanced expression of BMP6 inhibits hepatic fibrosis in non-alcoholic fatty liver disease.
Gut. 2015 Jun64(6):973-81. doi: 10.1136/gutjnl-2014-306968.

Kanuri G, Wagnerberger S, Landmann M, Prigl E, Hellerbrand C, Bischoff SC, Bergheim I.
Effect of acute beer ingestion on the liver: studies in female mice.
Eur J Nutr. 2015 Apr54(3):465-74. doi: 10.1007/s00394-014-0730-z.

Pannem RR, Dorn C, Hellerbrand C, Massoumi R.
Cylindromatosis gene CYLD regulates hepatocyte growth factor expression in hepatic stellate cells through interaction with histone deacetylase 7.
Hepatology. 2014 Sep60(3):1066-81. doi: 10.1002/hep.27209.

Riener MO, Thiesler T, Hellerbrand C, Amann T, Cathomas G, Fritzsche FR, Dahl E, Bahra M, Weichert W, Terracciano L, Kristiansen G.
Loss of anterior gradient-2 expression is an independent prognostic factor in colorectal carcinomas.
Eur J Cancer. 2014 Jul50(10):1722-30. doi: 10.1016/j.ejca.2014.04.012.

Valletta D, Czech B, Spruss T, Ikenberg K, Wild P, Hartmann A, Weiss TS, Oefner PJ, Müller M, Bosserhoff AK, Hellerbrand C.
Regulation and function of the atypical cadherin FAT1 in hepatocellular carcinoma.
Carcinogenesis. 2014 Jun35(6):1407-15. doi: 10.1093/carcin/bgu054.

Dorn C, Engelmann JC, Saugspier M, Koch A, Hartmann A, Müller M, Spang R, Bosserhoff A, Hellerbrand C.
Increased expression of c-Jun in nonalcoholic fatty liver disease.
Lab Invest. 2014 Apr94(4):394-408. doi: 10.1038/labinvest.2014.3.

Köhler UA, Kurinna S, Schwitter D, Marti A, Schäfer M, Hellerbrand C, Speicher T, Werner S.
Activated Nrf2 impairs liver regeneration in mice by activation of genes involved in cell-cycle control and apoptosis.
Hepatology. 2014 Aug60(2):670-8. doi: 10.1002/hep.26964.

Hellerbrand C.
Molecular targets for antifibrotic therapy in liver disease: using magic bullets for crossfire rather than a one-sided shotgun attack.
Gut. 2014 Jul63(7):1039-41. doi: 10.1136/gutjnl-2013-305908. No abstract available.

Pannem RR, Dorn C, Ahlqvist K, Bosserhoff AK, Hellerbrand C, Massoumi R.
CYLD controls c-MYC expression through the JNK-dependent signaling pathway in hepatocellular carcinoma.
Carcinogenesis. 2014 Feb35(2):461-8. doi: 10.1093/carcin/bgt335.

Publikationen

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014